Erythromelalgia Differential Diagnoses

  • Author: Joseph E Maakaron, MD; Chief Editor: Emmanuel C Besa, MD   more...
 
Updated: Feb 10, 2012
 
 

Diagnostic Considerations

With no specific diagnostic test available, maintaining a high index of suspicion is necessary to make the diagnosis. Failure to make the diagnosis and failure to recognize an associated myeloproliferative disorder are common medicolegal pitfalls.

In addition to the conditions listed in the differential diagnosis, other problems to be considered include the following:

  • Fabry disease
  • Peripheral neuropathy
  • Raynaud phenomenon
  • Vasculitis

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Joseph E Maakaron, MD  Research Fellow, Department of Internal Medicine, American University of Beirut, Lebanon

Disclosure: Nothing to disclose.

Coauthor(s)

Ali Taher, MD  Professor of Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Lebanon

Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD  Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Robert J Nardino, MD Director, Internal Medicine Residency Program, Assistant Clinical Professor, Department of Internal Medicine, Hospital of Saint Raphael, Yale University School of Medicine

Robert J Nardino, MD is a member of the following medical societies: American College of Physicians, Association of Program Directors in Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Andrea LM Silber, MD Medical Oncologist, Father Michael J McGivney Center for Cancer Care, Saint Raphael Hospital

Andrea LM Silber, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine and American Society of Preventive Oncology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References

  1. Drenth JP, van Genderen PJ, Michiels JJ. Thrombocythemic erythromelalgia, primary erythermalgia, and secondary erythermalgia: three distinct clinicopathologic entities. Angiology. Jun 1994;45(6):451-3. [Medline].

  2. Michiels JJ, Drenth JP, Van Genderen PJ. Classification and diagnosis of erythromelalgia and erythermalgia. Int J Dermatol. Feb 1995;34(2):97-100. [Medline].

  3. Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. Apr 1985;102(4):466-71. [Medline].

  4. Orstavik K, Weidner C, Schmidt R, et al. Pathological C-fibres in patients with a chronic painful condition. Brain. Mar 2003;126(Pt 3):567-78. [Medline].

  5. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. May 2003;78(5):603-12. [Medline].

  6. Mork C, Kalgaard OM, Kvernebo K. Impaired neurogenic control of skin perfusion in erythromelalgia. J Invest Dermatol. Apr 2002;118(4):699-703. [Medline].

  7. Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol. Jun 2005;57(6):785-8.

  8. Drenth JP, te Morsche RH, Guillet G, et al. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol. Jun 2005;124(6):1333-8.

  9. Michiels JJ, te Morsche RH, Jansen JB, Drenth JP. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch Neurol. Oct 2005;62(10):1587-90.

  10. Nassar MA, Stirling LC, Forlani G. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. Aug 24 2004;101(34):12706-11.

  11. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. Mar 2004;41(3):171-4. [Medline]. [Full Text].

  12. Han C, Dib-Hajj SD, Lin Z, Li Y, et al. Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain. Jul 2009;132:1711-22. [Medline].

  13. Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. Mar 2000;136(3):330-6. [Medline].

  14. Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med. Sep 1997;242(3):191-7. [Medline].

  15. Dupont E, Illum F, Olivarius Bde F. Bromocriptine and erythromelalgia-like eruptions. Neurology. May 1983;33(5):670. [Medline].

  16. Zheng ZM, Zhang JH, Hu JM, et al. Poxviruses isolated from epidemic erythromelalgia in China. Lancet. Feb 6 1988;1(8580):296. [Medline].

  17. Alhadad A, Wollmer P, Svensson A, Eriksson KF. Erythromelalgia: Incidence and clinical experience in a single centre in Sweden. Vasa. Jan 2012;41(1):43-8. [Medline].

  18. Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, Sandroni P, Davis MD, Davis DM. Pediatric erythromelalgia: A retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period. J Am Acad Dermatol. Jul 26 2011;[Medline].

  19. Cohen JS. High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother. Feb 2002;36(2):255-60. [Medline].

  20. Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. Oct 2005;141(10):1320-1.

  21. Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I, et al. Severe case and literature review of primary erythromelalgia: Novel SCN9A gene mutation. Vasc Med. Nov 9 2011;[Medline].

  22. Legroux-Crespel E, Sassolas B, Guillet G, et al. [Treatment of familial erythermalgia with the association of lidocaine and mexiletine]. Ann Dermatol Venereol. Apr 2003;130(4):429-33. [Medline].

  23. Iqbal J, Bhat MI, Charoo BA, et al. Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med. Jul-Aug 2009;29(4):316-8. [Medline].

  24. Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. Jan 2012;153(1):80-5. [Medline].

  25. Kalgaard OM, Mork C, Kvernebo K. Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study. Acta Derm Venereol. 2003;83(6):442-4. [Medline].

  26. Moody S, Pacheco S, Butler IJ, Koenig MK. Secondary Erythromelalgia Successfully Treated With Intravenous Immunoglobulin. J Child Neurol. Dec 7 2011;[Medline].

  27. Cacciola RR, Cipolla A, Di Francesco E, et al. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. Am J Hematol. Sep 2005;80(1):81-3.

 
Previous
Next
 
Cardinal symptoms of erythromelalgia.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.